Subscribe to our Newsletters !!

    Acalabrutinib Capsules

    Alembic Pharmaceuticals gets USFDA tentative approval for 100 mg Acalabrutinib capsules.

    Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Acalabrutinib Capsules, 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Calquence Capsules, 100 mg, of AstraZeneca UK Limited (AstraZeneca). Acalabrutinib Capsules are